Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts

The biotech company's stock received positive reviews from Wall Street research firms.

Apr. 8, 2026 at 8:13am

Got story updates? Submit your updates here. ›

An extreme close-up of intricately designed metal gears and machinery in shades of silver, steel, and black, conceptually representing the complex financial infrastructure that enables the biotech industry to function and innovate.The sophisticated financial and regulatory machinery that supports the biotech industry is a crucial but often unseen component of the sector's growth and innovation.Malvern Today

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned a consensus 'Moderate Buy' recommendation from the six analysts currently covering the company, according to Marketbeat. One analyst rated the stock as a 'sell', four gave 'buy' ratings, and one issued a 'strong buy' recommendation. The average 12-month price target among the analysts is $9.80 per share.

Why it matters

Aclaris Therapeutics is a clinical-stage biotech company focused on developing treatments for dermatological conditions. The 'Moderate Buy' rating from Wall Street analysts suggests they see potential in the company's pipeline of product candidates, including those targeting chronic inflammatory skin issues and non-melanoma skin lesions.

The details

Several research firms have recently weighed in on Aclaris Therapeutics. Weiss Ratings maintained a 'sell' rating on the stock, while Wedbush reiterated an 'outperform' rating and $8 price target. Wall Street Zen upgraded the stock from 'sell' to 'hold', and HC Wainwright kept a 'buy' rating with a $16 price target. Craig Hallum initiated coverage with a 'buy' rating and $10 target.

  • Aclaris Therapeutics stock opened at $3.75 on Wednesday, April 8, 2026.
  • The company's 200-day moving average price is $2.93, and its 52-week range is $1.05 to $4.89.

The players

Aclaris Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for dermatologic diseases and related rare disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The 'Moderate Buy' rating from Wall Street analysts suggests they see promise in Aclaris Therapeutics' pipeline of dermatology-focused drug candidates, even as the company continues to navigate the challenges of the biotech industry.